In this regard, phase II clinical trial of combinational therapy of anti-CTLA4 (Ipilimumab) with recombinant IFNα in treating melanoma patients is currently undergoing (ClinicalTrials.gov Identifier: NCT01708941) [22] suggesting that such a regimen might have potential benefit in cancer types with CNA of IFN gene cluster (e.g., kidney and brain cancers). Here, CTLA4 is linked to melanoma.